CKD-510
Development- Indications
- Neurological diseases, Cardiovascular diseases
Company intelligence / Profile preview
Kyongbo Pharmaceutical is a leading South Korean API manufacturer with cGMP certifications from FDA, EDQM, PMDA Japan, CFDA China. It produces various antibiotics especially cephalosporins along with finished dosage forms. It has expanded into CDMO services for high potency compounds. The company has partnered to distribute Can-Fite’s Phase III psoriasis drug Piclidenoson in South Korea. They export to over thirty countries globally with annual exports around $85 million worth of products. Their R&D focuses on developing new pharmaceutical substances while maintaining strong manufacturing capabilities. They have multiple plants dedicated to general APIs, sterile injectables, anticancer APIs etc.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kyongbo Pharmaceutical Co., Ltd.